Advances and applications of induced pluripotent stem cells
Abstract:Direct reprogramming of somatic cells into pluripotent cells is an emerging technology for creating patient-specific cells, and potentially opens new scenarios in medical and pharmacological fields. From the discovery of Shinya Yamanaka, who first obtained pluripotent cells from fibroblasts by retrovirus-derived ectopic expression of defined embryonic transcription factors, new methods have been developed to generate safe induced pluripotent stem (iPS) cells without genomic manipulations. This review will focus on the recent advances in iPS technology and their application in pharmacology and medicine.
Document Type: Research Article
Affiliations: Laboratory of Histology, Department of Health Sciences, Università del Piemonte Orientale “A. Avogadro”, Via Solaroli 17, 28100 Novara, Italy.
Publication date: March 16, 2012
More about this publication?
- Published since 1929, this monthly journal reports current research in all aspects of physiology, nutrition, pharmacology, and toxicology, contributed by recognized experts and scientists. It publishes symposium reviews and award lectures and occasionally dedicates entire issues or portions of issues to subjects of special interest to its international readership.
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Terms & Conditions
- Sample Issue
- Reprints & Permissions
- ingentaconnect is not responsible for the content or availability of external websites